Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2018 08:00 ET | Source: Savara

Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018

AUSTIN, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on Wednesday,...
October 15, 2018 08:00 ET | Source: Savara

Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP

Top Line Results Expected in Q2 2019 AUSTIN, Texas, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target...
September 27, 2018 08:00 ET | Source: Savara

Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data

AUSTIN, Texas, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided patient enrollment updates for its Molgradex pivotal Phase 3 clinical...
August 27, 2018 08:00 ET | Source: Savara

Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation

Savara and the PAP Foundation Form Global Partnership Which Will Support and Unite the Community of Individuals Afflicted with Pulmonary Alveolar Proteinosis (PAP) AUSTIN, Texas and LOS ANGELES, Aug....
August 02, 2018 08:00 ET | Source: Savara

Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018

AUSTIN, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday,...
July 26, 2018 09:15 ET | Source: Savara

Savara Announces Pricing of Public Offering of Common Stock

AUSTIN, Texas, July 26, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 4,250,000 shares of its...
July 25, 2018 16:16 ET | Source: Savara

Savara Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of...
July 25, 2018 16:01 ET | Source: Savara

Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF

Acquires assets of Cardeas and Announces Appointment of A. Bruce Montgomery, M.D., As Strategic Advisor AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung...
July 23, 2018 08:00 ET | Source: Savara

Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd

AUSTIN, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior...
June 25, 2018 08:00 ET | Source: Savara

Savara Joins Russell 3000® Index

AUSTIN, Texas, June 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company has been added to the broad-market Russell 3000 Index. ...